Skip to content

Stand UP to Rheumatoid Arthritis (SUPRA)

Rheumatoid Arthritis

Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Age ≥ 18 years;
* Arthritis that fulfills the 2010 ACR/EULAR classification criteria for RA;
* Failure to standard conventional synthetic DMARDs and eligible for second-line b/tsDMARDs (Sub-study 1) or failure to at least one TNF inhibitor and eligible for third-line b/tsDMARDs (Sub-study 2).

Exclusion Criteria:

* Prior b/tsDMARDs for Sub-study 1 or prior b/tsDMARDs other than TNF inhibitors for Sub-study 2;
* Contraindication to b/tsDMARD therapy, such as active infection or untreated latent TB, current malignancy, severe organ dysfunction, history of VTE (unless anticoagulated), high risk of cardiovascular disease, pregnancy/lactation;
* Overlap with another inflammatory disease requiring specific immunosuppressive therapy, such as lupus nephritis;
* Unable to provide consent or complete forms (alone or with assistance) in English or French

Study Location

Sir Mortimer B. Davis Jewish General Hospital
Sir Mortimer B. Davis Jewish General Hospital
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Marie Hudson, MD MPH

[email protected]
1-514-340-8222
Study Sponsored By
Sir Mortimer B. Davis - Jewish General Hospital
Participants Required
More Information
Study ID: NCT05305066